JP2021515010A5 - - Google Patents
Info
- Publication number
- JP2021515010A5 JP2021515010A5 JP2020545666A JP2020545666A JP2021515010A5 JP 2021515010 A5 JP2021515010 A5 JP 2021515010A5 JP 2020545666 A JP2020545666 A JP 2020545666A JP 2020545666 A JP2020545666 A JP 2020545666A JP 2021515010 A5 JP2021515010 A5 JP 2021515010A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkenyl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862636614P | 2018-02-28 | 2018-02-28 | |
| US62/636,614 | 2018-02-28 | ||
| PCT/US2019/019854 WO2019168999A1 (en) | 2018-02-28 | 2019-02-27 | Compounds with ferroptosis inducing activity and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515010A JP2021515010A (ja) | 2021-06-17 |
| JP2021515010A5 true JP2021515010A5 (enExample) | 2022-06-22 |
| JP7348906B2 JP7348906B2 (ja) | 2023-09-21 |
Family
ID=65729467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545666A Active JP7348906B2 (ja) | 2018-02-28 | 2019-02-27 | フェロトーシス誘導活性を有する化合物およびそれらの使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11098040B2 (enExample) |
| EP (1) | EP3759075B1 (enExample) |
| JP (1) | JP7348906B2 (enExample) |
| KR (1) | KR20200135961A (enExample) |
| CN (1) | CN112041301A (enExample) |
| AR (2) | AR114417A1 (enExample) |
| AU (1) | AU2019229256A1 (enExample) |
| BR (1) | BR112020017561A2 (enExample) |
| CA (1) | CA3092143A1 (enExample) |
| EA (1) | EA202091846A1 (enExample) |
| ES (1) | ES3038012T3 (enExample) |
| IL (1) | IL276788A (enExample) |
| MX (2) | MX2020008906A (enExample) |
| SG (1) | SG11202008230PA (enExample) |
| TW (1) | TW202000663A (enExample) |
| WO (1) | WO2019168999A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202045480A (zh) * | 2019-02-27 | 2020-12-16 | 美商費洛醫療公司 | 化合物及使用方法 |
| US11040964B2 (en) | 2019-02-27 | 2021-06-22 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| WO2021041539A2 (en) * | 2019-08-28 | 2021-03-04 | Ferro Therapeutics, Inc. | Compounds and methods of use |
| CN110511253B (zh) * | 2019-09-04 | 2023-10-13 | 上海药明康德新药开发有限公司 | DNA编码化合物库构建中On-DNA四氢-β-咔啉类化合物的合成方法 |
| CN110627786B (zh) * | 2019-10-29 | 2020-11-24 | 株洲千金药业股份有限公司 | 一种他达拉非中间体的制备方法 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US11998534B2 (en) * | 2020-02-12 | 2024-06-04 | Eubulus Biotherapeutics Inc. | GPX4 inhibitor in combination with anticancer agent for treating proliferative disease |
| JP2023518132A (ja) * | 2020-03-06 | 2023-04-27 | ベイジン・シノタウ・バイオ－ファーマシューティカルズ・テクノロジー・カンパニー，リミテッド | Ｃｔｂ００６とポナチニブとの併用の適用 |
| TW202227399A (zh) * | 2020-08-26 | 2022-07-16 | 美商費洛醫療公司 | 化合物及使用方法 |
| KR20230128471A (ko) * | 2020-12-04 | 2023-09-05 | 에우불루스 바이오테라퓨틱스 인코포레이티드 | 헤테로아릴-아세틸렌, 이의 약제학적 조성물, 및 이의치료적 적용 |
| WO2022216066A1 (ko) * | 2021-04-08 | 2022-10-13 | 서울대학교산학협력단 | 암 환자의 예후 예측용 바이오마커 및 이의 용도 |
| CN113336748B (zh) * | 2021-04-12 | 2022-03-25 | 北京大学 | 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物 |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| WO2024015637A1 (en) * | 2022-07-15 | 2024-01-18 | Ferro Therapeutics, Inc. | Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer |
| AU2023324856A1 (en) * | 2022-08-19 | 2025-01-30 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
| WO2024123412A1 (en) * | 2022-12-09 | 2024-06-13 | The University Of Toledo | Ferroptosis inducers to treat cancer |
| CN118994147B (zh) * | 2024-07-18 | 2026-01-02 | 中国海洋大学 | 一种基于疏水标签的gpx4蛋白降解剂及其制备方法和应用 |
| CN120923499A (zh) * | 2025-08-08 | 2025-11-11 | 兰州大学 | 一种铁死亡激动剂、缺氧响应型纳米共递送系统及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| JP2004501124A (ja) | 2000-06-07 | 2004-01-15 | リリー アイコス リミテッド ライアビリティ カンパニー | 化合物 |
| US20030153575A1 (en) | 2000-06-08 | 2003-08-14 | Orme Mark W. | Tetracyclic diketopiperazine compounds as pdev inhibitors |
| US6962918B2 (en) | 2000-10-02 | 2005-11-08 | Lilly Icos Llc. | Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction |
| MXPA03004023A (es) | 2000-11-08 | 2004-02-12 | Lilly Icos Llc | Compuestos quimicos. |
| AU2006275702A1 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
| EP1914235A1 (en) | 2006-10-10 | 2008-04-23 | Universite de Lille 2 Droit et Santé | Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| FR2916200A1 (fr) | 2007-05-18 | 2008-11-21 | Fourtillan Snc | Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique |
| US9169247B2 (en) | 2009-11-20 | 2015-10-27 | Southern Research Institute | Tetrahydro-beta-carboline derivatives, synthesis and use thereof |
| US9695133B2 (en) * | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| WO2015051149A1 (en) | 2013-10-04 | 2015-04-09 | The Trustees Of Columbia University In The City Of New York | Sorafenib analogs and uses thereof |
| EP3094332B1 (en) | 2014-01-15 | 2018-09-12 | The Trustees of Columbia University in the City of New York | Carbonyl erastin analogs and their use |
| US20170342021A1 (en) | 2014-12-16 | 2017-11-30 | Adt Pharmaceuticals, Inc. | Ras-inhibiting indenyl acetamide compounds, compositions, and uses |
| US10736972B2 (en) | 2015-05-29 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
| JP6592197B2 (ja) | 2015-11-12 | 2019-10-16 | 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． | アクリル酸誘導体、製造方法、および医薬としてのその使用 |
| US20190008961A1 (en) | 2016-01-07 | 2019-01-10 | The Broad Institute, Inc. | Compounds and methods for increasing tumor infiltration by immune cells |
| BR112018013730B1 (pt) | 2016-01-08 | 2022-06-28 | Championx Usa Inc. | Método para intensificar a produção e/ou o transporte de óleo bruto |
| KR102479822B1 (ko) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| WO2018118711A1 (en) | 2016-12-19 | 2018-06-28 | The Trustees Of Columbia University In The City Of New York | Small molecule ferroptosis inducers |
| EP3630089A4 (en) | 2017-05-24 | 2021-06-09 | Ferro Therapeutics, Inc. | PROCEDURE FOR CANCER THERAPY |
| US11530413B2 (en) | 2017-07-21 | 2022-12-20 | Novartis Ag | Compositions and methods to treat cancer |
| WO2019106434A1 (en) | 2017-12-01 | 2019-06-06 | Collaborative Medicinal Development Pty. Ltd. | Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders |
| US20200383943A1 (en) | 2017-12-04 | 2020-12-10 | Memorial Sloan Kettering Cancer Center | Methods of cancer treatment via regulated ferroptosis |
| CN109796424A (zh) | 2019-02-19 | 2019-05-24 | 四川大学 | 一种抑制铁死亡的小分子化合物及其制备方法与应用 |
| TW202045480A (zh) | 2019-02-27 | 2020-12-16 | 美商費洛醫療公司 | 化合物及使用方法 |
-
2019
- 2019-02-27 JP JP2020545666A patent/JP7348906B2/ja active Active
- 2019-02-27 WO PCT/US2019/019854 patent/WO2019168999A1/en not_active Ceased
- 2019-02-27 MX MX2020008906A patent/MX2020008906A/es unknown
- 2019-02-27 BR BR112020017561-7A patent/BR112020017561A2/pt not_active IP Right Cessation
- 2019-02-27 CA CA3092143A patent/CA3092143A1/en active Pending
- 2019-02-27 EP EP19710558.8A patent/EP3759075B1/en active Active
- 2019-02-27 US US16/287,805 patent/US11098040B2/en active Active
- 2019-02-27 ES ES19710558T patent/ES3038012T3/es active Active
- 2019-02-27 EA EA202091846A patent/EA202091846A1/ru unknown
- 2019-02-27 AU AU2019229256A patent/AU2019229256A1/en not_active Abandoned
- 2019-02-27 TW TW108106912A patent/TW202000663A/zh unknown
- 2019-02-27 CN CN201980028824.0A patent/CN112041301A/zh active Pending
- 2019-02-27 SG SG11202008230PA patent/SG11202008230PA/en unknown
- 2019-02-27 KR KR1020207027582A patent/KR20200135961A/ko not_active Withdrawn
- 2019-02-28 AR ARP190100499A patent/AR114417A1/es not_active Application Discontinuation
-
2020
- 2020-02-27 AR ARP200100540A patent/AR118205A1/es not_active Application Discontinuation
- 2020-08-18 IL IL276788A patent/IL276788A/en unknown
- 2020-08-26 MX MX2023001527A patent/MX2023001527A/es unknown
-
2021
- 2021-07-06 US US17/368,708 patent/US20230039846A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515010A5 (enExample) | ||
| AU2020394767B2 (en) | Spiro compound serving as ERK inhibitor, and application thereof | |
| RU2403251C2 (ru) | Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 | |
| JP2022522694A5 (enExample) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| IL275762B1 (en) | Derivatives of phenyl-so2-nh-c(=o)-phenyl-piperazine-ch2-1,2-cyclohexane-bicyclo[1.1.1]pentane and pharmaceutical compositions comprising them | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2009105826A (ru) | 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ | |
| RU2013156074A (ru) | Диазакарбазолы и способы применения | |
| KR20180050742A (ko) | 아레나비리다에 및 코로나비리다에 바이러스 감염의 치료 방법 | |
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| EA007867B1 (ru) | Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения | |
| KR101982951B1 (ko) | 신규한 유형의 시티딘 유도체 및 그의 용도 | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| RU2007110629A (ru) | Ингибиторы днк-пк | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| NZ608584A (en) | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations | |
| JP2017510660A5 (enExample) | ||
| BRPI0518068A (pt) | composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada | |
| WO2007132228A1 (en) | Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder | |
| RU2014153672A (ru) | Новые каберголиновые производные | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| JP2015502371A5 (enExample) | ||
| WO2008056264A3 (en) | Novel nucleotide analogues as percursor molecules for antivirals | |
| NZ545580A (en) | Aminoquinoline derivatives and their use as adenosine A3 ligands |